The effect of FTY720 in the Theiler's virus model of multiple sclerosis

J Neurol Sci. 2011 Sep 15;308(1-2):41-8. doi: 10.1016/j.jns.2011.06.029. Epub 2011 Jul 2.

Abstract

FTY720 (fingolimod) has demonstrated efficacy in multiple sclerosis (MS). We evaluated the effects of FTY720 on progressive disability, viral load, and antibody responses in mice infected with Theiler's murine encephalomyocarditis virus (TMEV). FTY720 and phosphorylated FTY720 (FTY720-P) were detected in the brain after intraperitoneal injection of the drug. Bioactivity of FTY720 was confirmed by reduced numbers of mononuclear cells in the spleen and blood after treatment. No significant differences were found in disability progression, viral load, and serum antibody responses between the FTY720-treated versus the PBS-treated mice. There was less production of IgG within the CNS in the FTY-treated group on some measures.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiovirus Infections / drug therapy
  • Cardiovirus Infections / immunology
  • Cardiovirus Infections / pathology
  • Disease Models, Animal*
  • Female
  • Fingolimod Hydrochloride
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Injections, Intraperitoneal
  • Mice
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology*
  • Multiple Sclerosis / virology*
  • Propylene Glycols / pharmacology
  • Propylene Glycols / therapeutic use*
  • Sphingosine / analogs & derivatives*
  • Sphingosine / pharmacology
  • Sphingosine / therapeutic use
  • Theilovirus / drug effects*
  • Theilovirus / immunology
  • Viral Load / drug effects
  • Viral Load / immunology

Substances

  • Immunosuppressive Agents
  • Propylene Glycols
  • Fingolimod Hydrochloride
  • Sphingosine